These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 573520)

  • 41. T cell-mediated immunity to oncornavirus-induced tumors. I. Ly phenotype of precursor and effector cytolytic T lymphocytes.
    Leclerc JC; Cantor H
    J Immunol; 1980 Feb; 124(2):846-50. PubMed ID: 6243332
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhancement of experimental tumors in mice by treatment with concanavalin A.
    Ekstedt RD
    J Natl Cancer Inst; 1979 Oct; 63(4):1065-9. PubMed ID: 480379
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Susceptibility and resistance to Moloney murine leukemia virus-induced promonocytic leukemia.
    Nazarov V; Hilbert D; Wolff L
    Virology; 1994 Dec; 205(2):479-85. PubMed ID: 7975249
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factors affecting passive monoclonal antibody therapy of Moloney sarcoma in BALB/c mice.
    Kennel SJ; Lankford PK; Flynn KM; Winegar R
    Cancer Res; 1985 Aug; 45(8):3782-9. PubMed ID: 2410101
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Requirements for T cells in alloantigen-induced generation of non-T cell-mediated cytotoxicity against syngeneic mouse sarcoma cells.
    Paciucci PA; Macphail S; Bach FH; Zarling JM
    J Immunol; 1980 Jul; 125(1):36-9. PubMed ID: 6155401
    [TBL] [Abstract][Full Text] [Related]  

  • 46. T-cell immunity to murine Moloney sarcoma virus-induced tumours: L3T4+ T cells are necessary for resistance to primary sarcoma growth, but Lyt-2+ T cells are required for resistance to secondary tumour cell challenge.
    Bateman WJ; Jenkinson EJ; Owen JJ
    Immunology; 1987 Jul; 61(3):317-20. PubMed ID: 2956180
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumors induced by progressor sarcoma virus (Moloney) in mice: growth in the presence of an immune response and isolation of autonomously growing cells.
    Weiland E; Mussgay M
    Arch Virol; 1980; 66(1):1-10. PubMed ID: 7436738
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunity against Moloney sarcoma virus in H-2Db mutant bm14 mice. Unimpaired tumor immunity despite absence of a virus-specific cytotoxic T-cell response.
    Stukart MJ; Boes J; Melief CJ
    Int J Cancer; 1984 Feb; 33(2):265-9. PubMed ID: 6319305
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of anti-interferon serum on growth and regression of Moloney sarcoma virus induced tumours in mice.
    Inglot AD; Oleszak E; Inglot O
    Acta Biol Med Ger; 1979; 38(5-6):829-35. PubMed ID: 525154
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Changes caused in the homing patterns of chromium 51-labeled lymphoid cells by Moloney sarcoma virus infection.
    Gillette RW; Fox A
    J Natl Cancer Inst; 1977 Jun; 58(6):1621-8. PubMed ID: 864743
    [No Abstract]   [Full Text] [Related]  

  • 51. Enhancement of Moloney sarcoma virus-induced tumor growth by concanavalin A.
    Davis S; Redmon LW; Pearson GR
    Immunol Commun; 1975; 4(1):29-37. PubMed ID: 1090515
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Decrease of cytotoxic immune lymphoid cells following regression of virus-induced sarcomas in mice.
    Levy JP; Lechlerc JC; Gomard E; Pavie J; Kourilsky F
    Bibl Haematol; 1973; 39():689-97. PubMed ID: 4798253
    [No Abstract]   [Full Text] [Related]  

  • 53. Inhibitory effects of xenogeneic antiserum on the growth of Moloney virus-induced sarcomas.
    Pierce GE
    J Surg Oncol; 1977; 9(3):249-56. PubMed ID: 875394
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibody-dependent cell-mediated cytotoxicity in the Moloney sarcoma virus system: no requirement for exogenous C5.
    Fuson EW; Walia AS; Cox BA; Lamon EW
    Clin Immunol Immunopathol; 1979 Sep; 14(1):35-46. PubMed ID: 477041
    [No Abstract]   [Full Text] [Related]  

  • 55. Protective effect of murine sarcoma virus-superinfected mouse tumor cells against outgrowth of corresponding noninfected tumor.
    Kuzumaki N; Fenyö EM; Klein E; Klein G
    Transplantation; 1978 Nov; 26(5):304-7. PubMed ID: 705875
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antibody-dependent, cell-mediated cytotoxicity with autochthonous lymphocytes and sera after infection with Moloney sarcoma virus.
    Lamon EW; Hale P; Whitten HD
    J Natl Cancer Inst; 1976 Feb; 56(2):349-55. PubMed ID: 1255765
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PET visualizes antitumor immune response.
    J Nucl Med; 2006 Jan; 47(1):20N, 22N. PubMed ID: 17061395
    [No Abstract]   [Full Text] [Related]  

  • 58. Polyclonal antibody synthesis and autoantibody formation in mice inoculated with murine sarcoma virus.
    Ishiyama H; Louis JA; Cerottini JC
    Clin Immunol Immunopathol; 1980 Mar; 15(3):456-64. PubMed ID: 6989530
    [No Abstract]   [Full Text] [Related]  

  • 59. In vitro demonstration of in situ autologous tumour-cell cytotoxicity in MSV-induced tumours in A/SN mice.
    Becker S; Haskill S
    Br J Cancer; 1981 Mar; 43(3):284-93. PubMed ID: 7053211
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Natural history of M-MSV tumors in mice carrying endogenized Moloney leukemia virus.
    Chieco-Bianchi L; D'Andrea E; De Rossi A; Zanovello P; Ronchese F; Collavo D
    Haematol Blood Transfus; 1983; 28():275-9. PubMed ID: 6602736
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.